Ginestet D, Peron-Magnan P, Deniker P
Pharmakopsychiatr Neuropsychopharmakol. 1976 Jul;9(4):183-6.
Long acting neuroleptics (L.A.N.) represent 11% of the medical prescription of neuroleptics in France (about 40,000 patients in 1974). Some psychiatrists remain reluctant to prescribe long acting-neuroleptics and many problems related to their use are still solved empirically:1) relation between the posology of the standard Neuroleptic and the corresponding L.A.N. 2)the problem of dose-interval. 3) the necessary prescription of an parkinsonian. The superiority of N.A.P. over the Neuroleptic Standard has received no experimental confirmation in France, but the L.A.N. appear to us as an original therapy, the "pivot chemotherapy" around which psychotherapy and sociotherapy can be arranged without anarchical and ceaseless changes of neuroleptic compounds and of posology.
长效抗精神病药物(L.A.N.)在法国抗精神病药物的医疗处方中占11%(1974年约有40000名患者)。一些精神科医生仍不愿开长效抗精神病药物,与其使用相关的许多问题仍凭经验解决:1)标准抗精神病药物的剂量与相应长效抗精神病药物之间的关系。2)剂量间隔问题。3)帕金森病药物的必要处方。在法国,非典型抗精神病药物(N.A.P.)相对于标准抗精神病药物的优越性尚未得到实验证实,但长效抗精神病药物在我们看来是一种原创疗法,是“关键化疗”,围绕它可以安排心理治疗和社会治疗,而无需抗精神病药物化合物和剂量的无规律且不断变化。